BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 19073820)

  • 1. Modern treatment of amyloidosis: unresolved questions.
    Dember LM
    J Am Soc Nephrol; 2009 Mar; 20(3):469-72. PubMed ID: 19073820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Treatment of amyloidosis].
    Wien TN
    Tidsskr Nor Laegeforen; 2008 Jun; 128(12):1397-400. PubMed ID: 18552901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heart transplantation in systemic (AL) amyloidosis: a retrospective study of eight French patients.
    Mignot A; Varnous S; Redonnet M; Jaccard A; Epailly E; Vermes E; Boissonnat P; Gandjbakhch I; Herpin D; Touchard G; Bridoux F
    Arch Cardiovasc Dis; 2008 Sep; 101(9):523-32. PubMed ID: 19041836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early intensification and autologous stem cell transplantation in patients with systemic AL amyloidosis: a single-centre experience.
    Frossard V; Ketterer N; Rosselet A; Meier P; Cairoli A; Duchosal MA; Kovacsovics T
    Ann Hematol; 2009 Jul; 88(7):681-5. PubMed ID: 19066891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An overview of high-dose melphalan and stem cell transplantation in the treatment of AL amyloidosis.
    Sanchorawala V; Seldin DC
    Amyloid; 2007 Dec; 14(4):261-9. PubMed ID: 17968685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary amyloidosis of the kidney.
    Shafique S; Wetmore J; Almehmi A
    W V Med J; 2010; 106(1):22-4. PubMed ID: 20088306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful reduced intensity allogeneic stem cell transplantation for systemic AL amyloidosis.
    Imamura T; Ogata M; Kohno K; Tomo T; Ohtsuka E; Kikuchi H; Kadota J
    Am J Hematol; 2006 Apr; 81(4):281-3. PubMed ID: 16550508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Immunoglobulin light chain amyloidosis: recent molecular, clinical and therapeutic approach].
    Thierry A; Bridoux F; Goodman H; Belmouaz S; Abou Ayache R; Desport E; Jaccard A; Touchard G
    Nephrologie; 2004; 25(4):111-8. PubMed ID: 15291138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone +/- thalidomide for systemic light-chain amyloidosis: results of a phase II trial.
    Cohen AD; Zhou P; Chou J; Teruya-Feldstein J; Reich L; Hassoun H; Levine B; Filippa DA; Riedel E; Kewalramani T; Stubblefield MD; Fleisher M; Nimer S; Comenzo RL
    Br J Haematol; 2007 Oct; 139(2):224-33. PubMed ID: 17897298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment options for severe cardiac amyloidosis: heart transplantation combined with chemotherapy and stem cell transplantation for patients with AL-amyloidosis and heart and liver transplantation for patients with ATTR-amyloidosis.
    Sack FU; Kristen A; Goldschmidt H; Schnabel PA; Dengler T; Koch A; Karck M
    Eur J Cardiothorac Surg; 2008 Feb; 33(2):257-62. PubMed ID: 18096396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Marked shrinkage of amyloid lymphadenopathy after an intensive chemotherapy in a patient with IgM-associated AL amyloidosis.
    Tazawa K; Katoh N; Shimojima Y; Matsuda M; Ikeda S
    Amyloid; 2009 Dec; 16(4):243-5. PubMed ID: 19922338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amyloidosis-associated kidney disease.
    Dember LM
    J Am Soc Nephrol; 2006 Dec; 17(12):3458-71. PubMed ID: 17093068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent advances in the management of AL Amyloidosis.
    Kastritis E; Dimopoulos MA
    Br J Haematol; 2016 Jan; 172(2):170-86. PubMed ID: 26491974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Diagnosis and treatment in systemic amyloidosis].
    Ikeda S
    Rinsho Byori; 2008 Feb; 56(2):121-9. PubMed ID: 18404826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful treatment of systemic amyloidosis with hepatic involvement and factor X deficiency by high dose melphalan chemotherapy and autologous stem cell reinfusion.
    Breems DA; Sonneveld P; de Man RA; Leebeek FW
    Eur J Haematol; 2004 Mar; 72(3):181-5. PubMed ID: 14962236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Advances in diagnosis and treatment of AL amyloidosis].
    Zelichowski G; Lubas A; Wańkowicz Z
    Pol Merkur Lekarski; 2008 Apr; 24(142):340-5. PubMed ID: 18634370
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AL amyloidosis manifesting as systemic lymphadenopathy.
    Matsuda M; Gono T; Shimojima Y; Yoshida T; Katoh N; Hoshii Y; Yamada T; Ikeda S
    Amyloid; 2008 Jun; 15(2):117-24. PubMed ID: 18484338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and histological responses of renal amyloidosis to high-dose melphalan supported by autologous stem cell transplantation.
    Sanada S; Suzuki M; Shindo T; Suzuki S; Nakamichi T; Matsubara M; Maeda K
    Nephrol Dial Transplant; 2008 Feb; 23(2):747-50. PubMed ID: 17989105
    [No Abstract]   [Full Text] [Related]  

  • 19. Waldenström's macroglobulinemia associated with serum amyloid A protein amyloidosis: pitfalls in diagnosis and successful treatment with melphalan-based autologous stem cell transplant.
    Muzaffar J; Katragadda L; Haider S; Abdallah AO; Anaissie E; Usmani SZ
    Acta Haematol; 2013; 130(3):146-9. PubMed ID: 23689541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myeloablative chemotherapy with stem cell rescue for the treatment of primary systemic amyloidosis: a status report.
    Gertz MA; Lacy MQ; Dispenzieri A
    Bone Marrow Transplant; 2000 Mar; 25(5):465-70. PubMed ID: 10713619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.